Cancer cells differ from normal cells because they don’t know when to stop growing. One way they do this is by getting rid of certain “tumor suppressor proteins” that would normally cause cancer cells to die. KPT-330 is an investigational drug designed to inhibit cancer growth by trapping tumor suppressor proteins inside cancer cells, causing them to die. KPT-330 is being evaluated in patients with different types of cancer.
In this study, researchers want to assess the effects of food (high-fat versus low-fat meal) and formulation (tablet versus capsule) on the way the body processes KPT-330 in patients with sarcoma of the bones or soft tissue. Patients will be randomly assigned to one of two treatment schedules in which they take the drug as a tablet and as a capsule on an empty stomach, with a low-fat meal, and with a high-fat meal over a four-week period.